-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Nabriva Therapeutics plc quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2014 to 2022.
- Nabriva Therapeutics plc Income Tax Expense (Benefit) for the quarter ending June 30, 2023 was $0.000, a 100% decline year-over-year.
- Nabriva Therapeutics plc annual Income Tax Expense (Benefit) for 2022 was $1.57M, a 220% increase from 2021.
- Nabriva Therapeutics plc annual Income Tax Expense (Benefit) for 2021 was $490K, a 253% increase from 2020.
- Nabriva Therapeutics plc annual Income Tax Expense (Benefit) for 2020 was $139K, a 37.6% increase from 2019.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)